Merdury Biopharmaceutical Corporation (TPEX:6932)
Taiwan · Delayed Price · Currency is TWD 5.51
+0.02 (0.36%)
Aug 19, 2026, 12:55 PM CST
Merdury Biopharmaceutical Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -51.62 | -67.23 | -50.57 | -43.82 | -31.25 | -5.31 |
Depreciation & Amortization | 11.48 | 11.64 | 7.45 | 4.07 | 2.75 | 0.97 |
Loss (Gain) From Sale of Assets | 0.72 | 0.62 | - | - | - | - |
Stock-Based Compensation | 0.39 | 0.55 | 1.24 | 1.82 | 1.13 | - |
Other Operating Activities | 0.06 | 0.06 | 0.46 | 0.29 | -0.02 | - |
Change in Accounts Receivable | 0.01 | 0.01 | -0.01 | - | - | - |
Change in Accounts Payable | 3.55 | 1.62 | 2.57 | 0.64 | 4.86 | 0.9 |
Change in Unearned Revenue | - | 0.31 | 5.04 | 0.44 | - | - |
Change in Other Net Operating Assets | -8.36 | 1.6 | -0.89 | -5.6 | -3.31 | -1.34 |
Operating Cash Flow | -45.99 | -50.84 | -34.71 | -42.15 | -25.84 | -4.78 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Capital Expenditures | -10.7 | -6.88 | -10.02 | -12.93 | -68.51 | -6.98 |
Sale (Purchase) of Intangibles | -0.36 | -0.42 | -1.08 | -0.65 | -0.14 | -0.53 |
Investment in Securities | 75.6 | 52.2 | 121.98 | -176.08 | -108.7 | - |
Other Investing Activities | -0.89 | -0.83 | -2.23 | -4.79 | -8.04 | -0.51 |
Investing Cash Flow | 63.65 | 44.08 | 108.65 | -194.44 | -185.4 | -8.02 |
Long-Term Debt Issued | - | - | - | - | 41.6 | - |
Long-Term Debt Repaid | - | -4.16 | -1.45 | -1.07 | -0.99 | -0.39 |
Net Debt Issued (Repaid) | -4.08 | -4.16 | -1.45 | -1.07 | 40.61 | -0.39 |
Issuance of Common Stock | 8.23 | 4.52 | 7.17 | 250 | 200 | 15.97 |
Repurchase of Common Stock | -8.56 | -8.56 | -56.24 | - | - | - |
Other Financing Activities | - | - | - | - | - | -0.3 |
Financing Cash Flow | -4.42 | -8.21 | -50.52 | 248.93 | 240.61 | 15.28 |
Foreign Exchange Rate Adjustments | -0.07 | 0.13 | 0.29 | 0.01 | - | - |
Net Cash Flow | 13.17 | -14.84 | 23.71 | 12.36 | 29.38 | 2.48 |
Free Cash Flow | -56.69 | -57.72 | -44.73 | -55.07 | -94.35 | -11.77 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | - | - | -901.17% | -5331.17% | -3520.60% | - |
Free Cash Flow Per Share | -0.13 | -0.14 | -0.11 | -0.14 | -0.25 | -0.04 |
Levered Free Cash Flow | -39.75 | -35.91 | -29.87 | -41.24 | -82.81 | -10.3 |
Unlevered Free Cash Flow | -39.22 | -35.35 | -29.37 | -40.8 | -82.56 | -10.3 |
Cash Interest Paid | 0.9 | 0.9 | 0.8 | 0.71 | 0.4 | 0.01 |
Cash Income Tax Paid | 0.07 | 0.07 | 0.34 | 0.21 | 0.02 | - |
Change in Working Capital | -7.02 | 3.53 | 6.71 | -4.51 | 1.56 | -0.45 |